瑞麗醫美(02135.HK)香港公開發售獲386倍認購 上限定價0.40港元/股
格隆匯 12 月 24日丨瑞麗醫美(02135.HK)發佈公告，公司全球發售3.425億股股份，其中香港發售股份1.7125億股，國際發售股份1.7125億股，另有15%超額配股權；最終發售價已釐定為每股發售股份0.40港元，每手買賣單位10000股；創升融資為獨家保薦人，預期股份將於2020年12月28日於聯交所主板掛牌上市。
根據國際配售初步提呈發售的發售股份僅獲足額認購，且已於國際配售中超額分配5137萬股股份。合共3.429億股國際配售股份(包括基石投資者認購數目)已獲認購，相當於國際配售項下初步可供認購的國際配售股份總數約1.1倍。根據香港公開發售初步提呈的香港發售股份獲極大幅超額認購。公司合共接獲138,113份有效申請，認購合共132.189億股香港發售股份，相當於香港公開發售初步可供認購的香港發售股份總數約386.0倍。
按每股發售股份最終發售價0.40港元計算及根據基石投資協議，基石投資者所認購的發售股份數目現已確定。昊海生物科技已認購5000萬股，途益香港已認購2500萬股，分別約佔全球發售項下初步可供認購發售股份的14.6%及7.3%；及緊隨全球發售完成後公司已發行股本總額的2.4%及1.2%(假設超額配股權未獲行使且不計及根據購股權計劃可能授出的任何購股權獲行使而可能發行的任何股份)。
按每股發售股份最終發售價0.40港元計算，假設超額配股權未獲行使，估計公司將收取的全球發售所得款項淨額約為7040萬港元。其中，估計所得款項總淨額約28.0%將用於為上海市新建醫療美容機構的資本支出及初始營運成本提供資金；約15.0%將用於浙江省醫療美容機構的潛在戰略性收購；約11.0%將用於購買醫療美容服務設備及醫療消耗品，以完善若干醫療美容診療，擴大醫療美容服務範圍；約8.0%將用於積極推廣集團的品牌；及約10.0%將用於集團的營運資金及其他一般企業用途。倘超額配股權獲悉數行使，則公司將於超額配股權獲行使後將予發行的5137.5萬股股份收取額外所得款項淨額約2060萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
